EVM
RCUS icon

Eaton Vance Management’s Arcus Biosciences RCUS Stock Holding History

Eaton Vance Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-192
Closed -$5K – 2975
2021
Q1 		$5K Buy
+192
New +$6.68K ﹤0.01% 2612

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Eaton Vance Management's RCUS Position: Q2 2021 in Review

Eaton Vance Management sold out of Arcus Biosciences (RCUS) in Q2 2021, closing a stake of 192 shares — an estimated $5K sold.

Eaton Vance Management first reported a position in RCUS in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 130 funds tracked by Wall St. Rank hold RCUS as of Q2 2021.

  • Eaton Vance Management reported no remaining Arcus Biosciences position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 192 Arcus Biosciences shares in Q2 2021, an estimated $5K.
  • Eaton Vance Management first reported a position in Arcus Biosciences in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Arcus Biosciences position peaked at $5K in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.